Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 23, Art. 16 (pp. 246-261)    |    2022       

»

Cardiotoxicity of proteasome inhibitors in multiple myeloma treatment: literature review and own data

N. Shnalieva, G. Salogub

FSUE "V.A. Almazov National Medical Research Center" of the Ministry of Health of the Russian Federation

Brief summary

Over the past 15 years, significant progress has been made in the treatment of multiple myeloma (MM), which is due to the introduction of new drugs into clinical practice, in particular, proteasome inhibitors (PI). Currently, 3 representatives of this group of drugs are used: bortezomib (1st generation PI), carfilzomib and ixazomib (next generation PI). There are various data in the literature regarding the toxicity profile of this group of drugs, and in particular, the cardiotoxicity of PI - the manifestations of cardiovascular complications in patients with MM receiving PI therapy are described, and a strategy for assessing risk factors, monitoring, prevention, as well as the treatment of this group of complications. This retrospective study evaluated the incidence and pattern of CV events with PI in combination therapy in patients with MM. Results were obtained indicating a low incidence of new cardiac events in patients receiving PI therapy, and the reversibility of these complications when appropriate cardioprotective, antiarrhythmic and anticoagulant therapy is prescribed.


Key words

multiple myeloma, proteasome inhibitors, bortezomib, carfilzomib, ixazomib, cardiotoxicity

Reference list

1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA. Improved survival in multiple myeloma and the impact of novel therapies. Blood, 2008


2. Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia, 2014


3. Michel Attal et al. Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial). Blood, 2015


4. M.A. Dimopoulos,P. Moreau,E. Terpos,M.V. Mateos,S. Zweegman,G. Cook,M. Delforge,R. Hájek,F. Schjesvold,M. Cavo,H. Goldschmidt,T. Facon,H. Einsele,M. Boccadoro,J. San-Miguel,P. Sonneveld,U. Mey. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, March, 2021


5. Michael G. Fradley et al. Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. British Journal of Haematology, 2017


6. Naif O. Al-Harbi. Carfilzomib-induced cardiotoxicity mitigated by dexrazoxane through inhibition of hypertrophic gene expression and oxidative stress in rats. Toxicology mechanisms and methods, 2016


7. Fradly MG et al. Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. British Journal of Haematology, 2018


8. Kristin D. Kistler, Jill Kalman et al. Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational, Retrospective, Cohort Study, Clinical Lymphoma, Myeloma & Leukemia, Vol. 17, No. 2, 89-96, 2016


9. Stewart AK, Rajkumar SV, Dimopoulos MA et al. Carfilzomib, lenalidomide and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015;372:142-52


10. Dimopoulos MA, Moreau P et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed and refractory multiple myeloma (ENDEAVOR): a randomized, phase 3, open-label, multicenter study. Lancet Oncology 2016; 17 (1); 27-38


11. Bringhen S, Milan A, D'Agostino M et al. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. J Intern Med. 2019 Jul;286(1):63-74.


12. Shah S, Bishnoi R, Jain A, Bejjanki H, Xiong S, Wang Y et al. Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis. Leukemia & Lymphoma, Volume 59, 2018 - Issue 11, 2557-2569


13. Wang, J Cheng et al. Clinical Picture of Patients With Any CHF or IHD Adverse Event in the Integrated Safety Analysis of Phase II Studies of Carfilzomib in Patients With Relapsed and/or Refractory MM. Oncology Journal, Hematologic Malignancies,2013


14. Siegel D., Martin T., Nooka A et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica, 2013;98(11):1753-61


15. Michael J. Management of carfilzomib-associated carfilzomib-associated cardiac adverse events. Clin Lymphoma Myeloma Leukemia. 2016;16:241-5


16. Jouni H. et al. Ixazomib cardiotoxicity: a possible class effect of proteasome inhibitors. American Journal of Hematology, 2017; 92:220-221


17. Krishna M. et al. Cardiotoxicity associated with bortezomib: A single-center experience. Journal of cancer research and therapeutics, 2017


18. Orciuolo E. et al. Unexpected cardiotoxicity in haematological bortezomib treated patients. British Journal of Haematology, 2007, 138, 396-403


19. Chakraborty R., Mukkamala S.K.R., Calderon N. Bortezomib-induced reversible left ventricular systolic dysfunction: A case report and review of literature. British journal of medical practitioners. 2013, Vol. 6, 4.


20. Diwadkar S., Patel A.A., Fradley M.G. Bortezomib-induced complete heart block and myocardial scar: the potential role of cardiac biomarkers in monitoring cardiotoxicity. Case reports in cardiology, Vol. 16, article ID 3456287


21. Meseeha M.G., Kolade V.O., Attia M.N. Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy. Journal of community hospital internal medicine perspectives, 2015 (5).


22. Voortman J, Giaccone G. Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer. 2006; 6:129


23. Hacuhanefloglu A., Tarkun P., Gonullu E. Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib. International Journal og Hematology 2008;88 (2); 219-222


24. Yi Xiao, Jin Yin, Jia Wei, Zhen Shang. Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: A systematic review and meta-analysis. PLOS, Vol. 9, 2014


25. Urova E.V., Semochkin S.V. Mnojestvennaya mieloma, oslojnennaya sopytstvyushei kardiologicheskoi patologiei. Gematologiya i transfyziologiya. 2017;62(3):140-146.


26. Memorandym ESC po lecheniu onkologicheskih zabolevanii i serdechno-sosydistoi toksichnosti, razrabotannii po egidoi komiteta po praktike ESC 2016. Rossiiskii kardiologicheskii jyrnal 3 (143), 2017.


27. V.S. Rajkumar et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncology 2014; 15; 538-548


28. Management of systemic AL amyloidosis. Clinical practice guidelines. Medical scientific advisory group (MSAG) to the myeloma foundation of Australia (MFA), 2015


29. Weijuan L., Garcia D. et al. Cardiovascular and thrombotic complications of novel multiple myeloma therapies: a review. JAMA Oncology, 2016


30. Barry J. Maron et al. AHA Contemporary definitions and classification of the cardiomyopathies. Circulation, 2006; 113; 1807-1816


31. Sara Bringhen 1 , Roberto Mina 2 , Maria Teresa Petrucci 3 , Gianluca Gaidano 4 , Stelvio Ballanti et al. Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies. Haematologica. 2019 Aug;104(8):1640-1647.


32. Chari A, Stewart AK, Russell SD, Moreau P, Herrmann J, Banchs J, Hajek R, Groarke J, Lyon AR, Batty GN, Ro S, Huang M, Iskander KS, Lenihan D. Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. Blood Adv. 2018 Jul 10;2(13):1633-1644.


33. Alexander R. Lyon, Mohsen Habibian; Ruben Evertz, Riccardo Asteggiano; Thomas Suter. Diagnosis and treatment of left ventricular dysfunction and heart failure in cancer patients. E-Journal of Cardiology Practice Vol. 16, N? 40 - 27 Feb 2019


34. Stuart D Russell, Alexander Lyon, Daniel J. Lenihan et al. Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866), Blood, Volume 126, Issue 23,2015.


35. Jain, T., Narayanasamy, H., Mikhael, J. et al. Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma. Blood Cancer Journal 7, 642 (2017).


36. Cornell RF, Ky B, Weiss BM et al. Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. J Clin Oncol. 2019 Aug 1;37(22):19